

UC San Diego

School of Medicine

Division of Gastroenterology & Hepatology



#18
GASTROENTEROLOGY
& GI SURGERY

UC San Diego Health



UC San Diego #1 for
Gastroenterology &
Hepatology Research

Dear Colleagues and Friends,

I am delighted to share with you the highlights from the first quarter in our Division of Gastroenterology (GI) and Hepatology, illustrating our continued excellence and growth in research, education, and clinical practice. We are guided by our purpose and driven by our ambition to be the leading GI and liver clinical and research program in the world, and remain a beacon of innovation and collaboration in education, patient care, outreach, research and philanthropy.

We have maintained our strategic fit by investing in our team and by our strong alignment with the health system, the department, the school of medicine and the global academic community.

Research Excellence: Our division has published a series of high-impact papers that underscore our commitment to advancing medical knowledge. These publications, combined with our robust research projects, continue to position us at the forefront of digestive disease sciences. We continue to excel in our depth and breadth of research funding.

Educational Achievements: We have enhanced our educational programs to provide cutting-edge training for our fellows and staff. Our initiatives are designed to foster learning and professional growth, ensuring that we remain leaders in medical education.

Team Expansion: This quarter, we welcomed new members to our team, further strengthening our clinical and research capabilities. Each new addition brings a wealth of expertise and enthusiasm to our division.

Clinical Expansion: We continue to expand our clinical services, reaching more patients and refining our approach to patient care. Our efforts are aimed at delivering superior treatment and improving patient outcomes.

Collaborative Framework: The vibrant culture within our division is highlighted through numerous interactions and social events involving our faculty, fellows, and staff. These activities not only strengthen our team but also foster a cohesive and supportive environment. We are delighted to work in close collaboration with our colleagues in surgery and other streams of medicine.

Resilience Amid Challenges: Despite facing new funding challenges and changes in indirect costs by the NIH, our division remains resilient. We are adapting to these changes while continuing to thrive and advance our tripartite mission of research, education, and clinical care.

Gratitude to Supporters: We are immensely grateful to our philanthropic supporters, including the Step family, the Hammond family, and the John C. Martin Foundation. Their continued backing is pivotal to our success and enables us to push the boundaries of what we can achieve.

Looking forward, we are excited about the future and confident in our trajectory across all domains. Thank you for your ongoing support and commitment to our division.

Warm regards,
Rohit



Rohit Loomba, MD, MHS
Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Director, MASLD Research Center

FACULTY SPOTLIGHT

DR. BARBARA JUNG. M.D.

Dr. Jung is a practicing gastroenterologist with expertise in gastrointestinal diseases and has a clinical focus in hereditary GI diseases. Dr. Jung's research interests include both clinical and basic GI approaches, and she has a strong record of fostering collaboration between basic, translational and clinical research.

Her laboratory centers on TGFbeta and activin A signaling in GI disease, including colorectal cancer, pancreatitis and pancreatic cancer. Understanding the changes in pro-metastatic cell signaling pathways in colorectal and pancreatic cancer is critical to the development of new therapeutic approaches and for the development of individualized treatment regimens. Loss of TGFbeta signaling in human colon tumors is associated with increased inflammatory burden. Dr. Jung's work has highlighted the role for both TGFbeta and activin A in epithelial-stromal interactions driving tumorigenesis in both colorectal and pancreatic cancer. Dr. Jung's research has identified activin A expression was significantly higher in pancreatic cancer patients, with expression in stroma correlated with shorter survival. Since pancreatic cancer has a high stiffness and stromal cells play a critical biophysical role in cancer

progression, we found in CRC that increased tumor microenvironment stiffness leads to stromal cell mediated activin A signaling. Recently, Dr. Jung's research team was awarded a grant from the Department of Defense to investigate the role for activin A in acute pancreatitis. Her research group was able to show that increased activin A levels in acute pancreatitis is associated with worse patient outcome and that blocking activin A in a mouse model of acute pancreatitis reduces mortality.

Dr. Jung is an academician at heart and passionate about leading with empathy and through the empowerment of others. She is passionate about training the next generation of diverse clinicians, educators, scientists and leaders. Dr. Jung has been funded numerous times by the NIH and the Department of Defense and has over 67 original research papers and reviews articles that have been cited many times in high impact publications in Gastroenterology, Gut, and Scientific Reports.



TOP 3 PUBLICATIONS

- [Activin A signaling stimulates neutrophil activation and macrophage migration in pancreatitis](#). Wiley MB, Bauer J, Alvarez V, Mehrotra K, Cheng W, Kolics Z, Giarrizzo M, Ingle K, Bialkowska AB, **Jung B**, Sci Rep. 2024 Apr 23;14(1):9382. doi: 10.1038/s41598-024-60065-y. PMID: 38654064; PMCID: PMC11039671.
- [Author Correction: Increased stiffness of the tumor microenvironment in colon cancer stimulates cancer associated fibroblast-mediated prometastatic activin A signaling](#). Bauer J, Emon MAB, Staudacher JJ, Thomas AL, Zessner-Spitzenberg J, Mancinelli G, Krett N, Saif MT, **Jung B**. Sci Rep. 2020 Apr 30;10(1):7606. doi: 10.1038/s41598-020-64239-2. Erratum for: Sci Rep. 2020 Jan 9;10(1):50. doi: 10.1038/s41598-019-55687-6. PMID: 32355318; PMCID: PMC7192933.
- [Activin in acute pancreatitis: Potential risk-stratifying marker and novel therapeutic target](#). Staudacher JJ, Yazici C, Carroll T, Bauer J, Pang J, Krett N, Xia Y, Wilson A, Papachristou G, Dirmeier A, Kunst C, Whitcomb DC, Fantuzzi G, **Jung B**. Sci Rep. 2017 Oct 6;7(1):12786. doi: 10.1038/s41598-017-13000-3. PMID: 28986573; PMCID: PMC5630611.



FACULTY SPOTLIGHT

DR. GUILLAUME URTECHO

Dr. Guillaume Urtecho is an Assistant Professor in the Division of Gastroenterology and Hepatology through the UCSD FIRST program. Originally from California's Central Valley, he earned his B.S. in Genetics from UC Davis and his Ph.D. in Molecular Biology from UCLA. He completed his postdoctoral training at Columbia University Irving Medical Center under Dr. Harris Wang, where he studied microbiome spatiotemporal dynamics following Fecal Microbiota Transplantation (FMT).

Outside of his research, Guillaume is passionate about science education, mentorship, and promoting diversity and inclusion in STEM. He looks forward to advancing his research program and contributing to the UCSD community. Guillaume is supported by the Howard Hughes Medical Institute's Hanna H. Gray Program.



Dr. Urtercho's research group focuses on understanding microbial communities in the mammalian gut and developing innovative strategies to engineer these communities for therapeutic applications.



Urtecho Lab

RESEARCH

Using approaches guided by Systems Biology, Synthetic Biology, and Microbial Ecology, his lab investigates the complex interactions within gut microbiomes to design targeted interventions for gastrointestinal health. His current projects include developing methods to predict FMT outcomes using metabolic models and high-throughput approaches to explore how the microbiome's genetic 'dark matter' influences microbial fitness and host-microbe interaction.

TOP PUBLICATIONS

- [Spatiotemporal dynamics during niche remodeling by super-colonizing microbiota in the mammalian gut.](#) **Urtecho, Guillaume**, et al. Cell Systems 15.11 (2024): 1002-1017.
- [Genome-wide Functional Characterization of Escherichia coli Promoters and Sequence Elements Encoding Their Regulation.](#) **Urtecho, Guillaume**, et al. eLife 12 (2023).
- [SAMPL-seq reveals micron-scale spatial hubs in the human gut microbiome.](#) Richardson M, Zhao S, Lin L, Sheth RU, Qu Y, Lee J, Moody T, Ricaurte D, Huang Y, Velez-Cortes F, **Urtecho G**, Wang HH. Nat Microbiol. (2025)

Welcome New Faculty



Dr. Selena Kuo

Selena Kuo is a transplant hepatologist with an interest in alcohol related liver disease and hepatocellular carcinoma. Selena was born and raised in the Bay Area and received her medical degree from the University of California, San Francisco. She went on to complete her internal medicine residency at Columbia University. She returned to California to complete her gastroenterology and transplant hepatology fellowships at UC San Diego.

Outside of work, Selena enjoys spending time with family and friends, snorkeling, hiking and traveling. She is excited to join the hepatology group at UCSD!

Eric Low, MD, MPH is a new Assistant Clinical Professor at UCSD and the VA with an interest in esophageal motility disorders and eosinophilic GI disorders. Eric received his masters in public health from the University of Loma Linda with a focus on epidemiology and biostatistics. He received his medical degree from the University of California, San Francisco School of Medicine. He completed Internal Medicine residency as well as GI fellowship (T32), GI Chief year, and an advanced GI esophageal fellowship at the University of California, San Diego. Eric's research as a GI fellow resulted several first author publications and several awards of distinction. Notably he was awarded the ACG Governor's award for Excellence in Research. During his advanced esophageal year, Dr. Low received a notice of intent to fund for a VA Career Development Award (5-year grant) which focuses on uncovering EoE genetic and environmental risk factors. He has also began developing an EoE/EGID-focused clinical program at UCSD.

Outside of work, Eric enjoys snowboarding, hiking, biking, surfing, and hanging out at the beach with his wife (Maria) and son (George).



Dr. Eric Low

Welcome New Physician Assistants

We are pleased to welcome Physician Assistant Abha Bosworth to UCSD. Abha joins us with 20 years of General GI experience, with a special interest in Inflammatory Bowel Disease. She previously worked in outpatient GI medical groups affiliated with Sharp Grossmont and Scripps Mercy Hospitals. Abha obtained her Master of Science degree in Physician Assistant Studies from Western University of Health Sciences.

Prior to this, she received her Bachelor of Science degree from UCSD and her Master of Public Health degree in Epidemiology from San Diego State University. Outside of work, Abha enjoys spending time with her husband and two children, traveling, and coaching a world-winning high school FIRST robotics team.



Abha Bosworth, MPH, MS, PA-C



Mara Custodio, MPA, PA-C is a Board-Certified Physician Assistant who earned her Master in Physician Assistant Studies from Eastern Virginia Medical School. She completed her undergraduate degree at the University of California, Los Angeles (UCLA), where she also conducted clinical research in Rheumatoid Arthritis, resulting in publications in medical journals.

Prior to joining UCSD Gastroenterology/Hepatology, Ms. Custodio worked in private practice and academic settings, including UCLA and Loma Linda University. She has a strong commitment to community service, volunteering in under served areas-from empowering children in Los Angeles through summer camps to participating in the Stanford University medical mission to indigenous villages of Papua New Guinea.

In her personal time, Ms. Custodio enjoys traveling, exploring new cuisines, stand-up comedy, and indulging in a good boba milk tea.

Mara Custodio, MPA, PA-C

ACG 2025 Leonidas Berry Health Equity Research Award & SDDRC Pilot & Feasibility Award

We would like to congratulate Dr. Monica Tincopa on the recent receipt of two research grant awards for her work on health disparities for Hispanic/Latino populations with MASLD. As an investigator in the UCSD MASLD Research Center, Dr. Tincopa's research interests include evaluation of health disparities in chronic liver disease, liver transplantation and MASLD. She has specific focus on MASLD within the Hispanic/Latino population including improving access to care and optimizing risk stratification and treatment.

Dr. Tincopa was selected as a recipient of the one year San Diego Digestive Diseases Research Center (SDDRC) Pilot & Feasibility award and the two year American College of Gastroenterology (ACG) Leonidas Berry Health Equity Research Award to continue to build on her work to design actionable interventions to move towards health equity in MASLD for Hispanic individuals. This work will focus on optimizing screening, care access, and non-invasive testing for Hispanic individuals with MASLD.



Past Events

Division Chief Lunch with Fellows







SDDRC SYMPOSIUM



DEPARTMENT

PICKLEBALL EVENT



LET'S PLAY!

On March 8th, faculty, staff, fellows, and family came together for a friendly pickleball showdown—serving up fun and smashing good times. The event was held at the King of Padel Sports Club in San Diego.

Don't miss out on the next round—come join the action and let's keep the fun rolling!

SUPPORT
**Screen Your Gut-
Save Your Butt**

**Run to defeat
COLORECTAL
CANCER**

You're Invited!
5K Timed Run/Walk
Saturday, March 29, 2025
8am-Noon Mission Bay, San Diego, CA

C4 California
Colorectal
Cancer
Coalition
www.cacoloncancer.org

To register: <https://charity.pledgeit.org/C4SanDiego>

Join the fun in Mission Bay Park, San Diego, on March 29, 2025 to raise awareness and to promote prevention and early detection of colorectal cancer. The California Colorectal Cancer Coalition (C4) is a nonprofit organization made up of a diverse group of dedicated individuals from throughout California whose mission is to save lives and reduce suffering from colorectal cancer in all Californians.

Funds raised through the “Screen Your Gut – Save Your Butt” run will be used for the C4 Community Grants Program that aims to increase screening to prevent colorectal cancer development and detect existing cancers earlier when the outcomes are more favorable for patients.

To register: <https://charity.pledgeit.org/C4SanDiego>

ADVANCES IN GASTROENTEROLOGY & HEPATOLOGY CME 2025

INVITED SPEAKERS



Hiro Aihara, MD PhD
Director, Endoscopic Tissue
Resection,
Brigham & Women's Hospital
Associate Professor of
Medicine,
Harvard Medical School



Nancy S. Reau, MD
Section Chief, Hepatology
Associate Director of Organ
Transplantation
Professor, Dept. of Internal
Medicine, Division of
Digestive
Diseases & Nutrition
Rush University



SATURDAY, APRIL 12, 2025



7:00 AM - 4:30 PM



**ALTMAN CLINICAL
TRANSLATIONAL RESEARCH
INSTITUTE (ACTRI)
1W-210 AUDITORIUM**

COURSE DIRECTORS



PRANAB BARMAN, MD
ASSOCIATE CLINICAL PROFESSOR
UCSD, DIVISION OF GI & HEPATOLOGY



BRIGID BOLAND, MD
ASSOCIATE PROFESSOR OF MEDICINE
UCSD, DIVISION OF GI & HEPATOLOGY



ROHIT LOOMBA, MD
DIVISION CHIEF
UCSD, DIVISION OF GI & HEPATOLOGY

Course Objectives

- Understand the novel approaches to the diagnosis and management of Barrett's esophagus
- Identify current treatment approaches for GERD
- Discuss the management techniques for celiac disease
- Develop an understanding of the role artificial intelligence technologies in colon cancer screening, management of inflammatory bowel disease and chronic liver disease
- Recall the updated landscape for novel therapeutics in inflammatory bowel disease
- Understand the role of new pharmaceutical agents in the management of metabolic associated steatohepatitis
- Understand the management considerations for alcoholic liver disease, including early liver transplantation
- Identify the role and utility of endoscopic submucosal dissection
- Discuss the techniques for diagnosing and managing pancreatic cysts

SAVE-THE-DATE

16th Annual Research Symposium
Novel Insights in Mucosal Immunology & Advances in IBD

Friday, May 2, 2025
MET
Lower Auditorium
10:30 AM - 5:00 PM

Hosted By
IBD Course Directors
Siddarth Singh, MD
Brigid Boland, MD
John Chang, MD



Career Development Club

The San Diego Digestive Diseases Research Center (SDDRC) holds a regular Career Development Club to promote the academic career development of SDDRC members and their academic staff, members of the Gastroenterology Division, and the broader academic community dedicated to advancing research in digestive diseases.

The Club is an outgrowth of a former K-Club directed by Dr. Rohit Loomba and designed to help junior faculty in GI and related fields obtain K-level (such as K08 or K01) NIH funding. The meetings provide opportunities for faculty, particularly early-stage faculty, to present and discuss projects that are at various stages of grant preparation from Career Development Awards and K-awards to full research grants at the R and U levels. The goal of the Club meetings is for presenters to receive feedback for work-in-progress and elicit critical input on strategies for conceiving and writing new applications or addressing critiques from already reviewed grants. The meetings are highly interactive with lively discussions and are led by several highly experienced faculty, including Dr. Rick Boland (former Division Chief of the UCSD GI Division), Dr. Lars Eckmann (SDDRC Co-Director), and Dr. Rohit Loomba (GI Division Chief).

All trainees and faculty are invited and encouraged to join the Club meetings, which are held in-person (lunch provided) with a hybrid Zom option on the last Thursday of the month at noon in ACTRI Room 1W516. Trainees and faculty interested to present at one of the meetings should contact the SDDRC Coordinator Victoria Shokrollah at vshokrollah@health.ucsd.edu for available dates.



Richard Boland, MD
Emeritus Professor
UC, San Diego



Rohit Loomba, MD, MHSc
Professor of Medicine
Chief, Division of GI &
Hepatology
Director of MASLD
Research Center



Lars Eckmann, MD
Professor of Medicine
Co-Director of SDDRC

SDDRC 2025 Upcoming Seminar Series:

Date	Speaker	Affiliation
3/24/25	Gretchen Diehl, PhD	Weill Cornell School of Medicine
4/30/25	John Mark Gubatan, MD	Stanford University School of Medicine
5/19/25	Suzanne Devkota, PhD	Cedars-Sinai
6/25/25	Jessica B. Rubin, MD, MPH	University of California, San Francisco
7/28/25	Renee M. Tsois, PhD	University of California, Davis
8/25/25	Arthur "Art" Beyder, M.D., Ph.D., AGAF	Mayo Clinic
9/29/25	Wen-Xing Ding, PhD, FAASLD	The University of Kansas
10/27/25	TBD	TBD
11/19/25	Folasade (Fola) P. May, MD, PhD, MPhil	University of California, Los Angeles
12/15/25	Howard Hang, Ph.D.	Scripps Research

Recent Publications

Number of publications linked in parentheses for each faculty since January 1, 2024; Please visit their linked PubMed profiles to view additional publications lists.

Ajmera, Veeral (32)

- [The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.](#) Bridi L, Agrawal S, Tesfai K, Madamba E, Bettencourt R, Richards LM, Khera AV, Loomba R, **Ajmera V**. Aliment Pharmacol Ther. 2024 Aug;60(3):369-377. doi: 10.1111/apt.18099. Epub 2024 Jun 2.
- [A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.](#) Mittal N, Siddiqi H, Madamba E, Richards L, Bettencourt R, **Ajmera V**, Loomba R. Aliment Pharmacol Ther. 2024 Jun;59(12):1571-1578. doi: 10.1111/apt.17997. Epub 2024 Apr 8.
- [Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.](#) Yang AH, Tincopa MA, Tavaglione F, **Ajmera VH**, Richards LM, Amangurbanova M, Butcher C, Hernandez C, Madamba E, Singh S, Bettencourt R, Schnabl B, Sirlin CB, Loomba R. Gut. 2024 Aug 7:gutjnl-2024-332917. doi: 10.1136/gutjnl-2024-332917. Online ahead of print.
- [Psychosocial predictors of return to alcohol use after liver transplant: A multicenter cohort study.](#) Torosian K, Shahrvini B, Johnson WM Jr, Vodkin I, Tincopa M, Lim N, Kwong A, **Ajmera V**. Alcohol Clin Exp Res (Hoboken). 2024 Sep 10. doi: 10.1111/acer.15438. Online ahead of print.
- [Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study.](#) 2024 "Tabrizian P, Holzner M, **Ajmera V**, Kim AK, Zhou K, Schnickel GT, Torosian K, Hoteit M, Marino R, Li M, Yao F, Florman SS, Schwartz ME, Mehta N. J Hepatol. 2024 Sep 8:S0168-8278(24)02541-8. doi: 10.1016/j.jhep.2024.09.003. Online ahead of print." 2024 Sep - "Tabrizian P, Holzner M, **Ajmera V**, Kim AK, Zhou K, Schnickel GT, Torosian K, Hoteit M, Marino R, Li M, Yao F, Florman SS, Schwartz ME, Mehta N.

Anand, Gobind (4)

- [Diagnostic methods to measure spastic segment and guide tailored myotomy length in type 3 achalasia.](#) Low EE, Hasan A, Fehmi SA, Chang MA, Kwong W, Krinsky ML, **Anand G**, Greytak M, Kaizer A, Yadlapati R. Neurogastroenterol Motil 2023 Jun 8; e14625.doi:10.1111/nmo.14625.
- [Pancreatic cyst features predict for future development of pancreatic cancer: Results of a nested case-control study.](#) Youssef FF, Liu L, Lin W, Bustamante R, Earles A, Savides T, Fehmi S, Kwong W, Gupta S, **Anand G**. Gastrointest Endosc. 2023 Oct 17:S0016-5107(23)02978-4. doi: 10.1016/j.gie.2023.10.038. Online ahead of print.
- [Esophageal anatomy and physiology vary across spastic and non-spastic phenotypes of disorders of esophagogastric junction outflow.](#) Vahedi F, Low EE, Kaizer AM, Fehmi SA, Hasan A, Chang MA, Kwong W, Krinsky ML, **Anand G**, Greytak M, Yadlapati R. Neurogastroenterol Motil. 2023 Nov 27:e14709. doi: 10.1111/nmo.14709.
- [Response.](#) Youssef FF, Gupta S, Anand G. Gastrointest Endosc. 2024 Apr;99(4):663-664. doi: 10.1016/j.gie.2023.12.005.

Barman, Pranab (8)

- [Portal vein thrombosis: Before, during, and after liver transplant.](#) Toth JF 3rd, **Barman P**. Clin Liver Dis (Hoboken). 2023 Jun 15;22(1):14-17. doi: 10.1097/CLD.000000000000067. eCollection 2023 Jul.
 - [Palliative care and end of life care in decompensated cirrhosis.](#) Miller K, **Barman P**, Kappus M. Clin Liver Dis (Hoboken) 2023 Jun 15; 22(1): 10-13.
-

- [Successful treatment of hepatitis C virus infection in patients on anti-epileptics or mood stabilizers using pharmacokinetic enhancers](#). Yin J, Hill L, Mansour M, Collier S, **Barman P**. Br J Clin Pharmacol 2023 Jun; 89(6): 1891-1895.
- [Opioid use and risks in candidates and recipients of liver transplant](#). Rubin JB, Aby ES, **Barman P**, Tincopa M. Liver Transpl. 2024 Apr 29. doi: 10.1097/LVT.0000000000000388. Online ahead of print.
- [Lessons Learned From the Liver About the Undergraduate to Graduate Medical Education Transition](#). Pan AY, Khorsandi PJ, Farnan JM, German MN, **Barman PM**, Berschback MA, Kriss M, McMillan R, Mousa O, Peng FB, Randhawa T, Scales K, Mikolajczyk AE. Am J Med Open. 2024 Nov 5;13:100079. doi: 10.1016/j.ajmo.2024.100079. PMID: 39817205; PMCID: PMC11730576.

Boland, Brigid (33)

- [Challenges in IBD Research 2024: Precision Medicine](#). Syed S, **Boland BS**, Bourke LT, Chen LA, Churchill L, Dobes A, Greene A, Heller C, Jayson C, Kostiuik B, Moss A, Najdawi F, Plung L, Rioux JD, Rosen MJ, Torres J, Zulqarnain F, Satsangi J. Inflamm Bowel Dis. 2024 May 23;30(Supplement_2):S39-S54. doi: 10.1093/ibd/izae084.
- [A living organoid biobank of patients with Crohn's disease reveals molecular subtypes for personalized therapeutics](#). Tindle C, Fonseca AG, Taheri S, Katkar GD, Lee J, Maity P, Sayed IM, Ibeawuchi SR, Vidales E, Pranadinata RF, Fuller M, Stec DL, Anandachar MS, Perry K, Le HN, Ear J, **Boland BS**, Sandborn WJ, Sahoo D, Das S, Ghosh P. Cell Rep Med. 2024 Oct 15;5(10):101748. doi: 10.1016/j.xcrm.2024.101748. Epub 2024 Sep 26. PMID: 39332415; PMCID: PMC11513829.
- [Approach to Therapy for Chronic Pouchitis](#). Kayal M, **Boland B**. Annu Rev Med. 2025 Jan;76(1):167-173. doi: 10.1146/annurev-med-032224-120544. PMID: 39869428.
- [Tissue-resident memory CD8 T cell diversity is spatiotemporally imprinted](#). Reina-Campos M, Monell A, Ferry A, Luna V, Cheung KP, Galletti G, Scharping NE, Takehara KK, Quon S, Challita PP, **Boland B**, Lin YH, Wong WH, Indralingam CS, Neadeau H, Alarcón S, Yeo GW, Chang JT, Heeg M, Goldrath AW. Nature. 2025 Jan 22. doi: 10.1038/s41586-024-08466-x. Epub ahead of print. PMID: 39843748.
- [Automated spatial omics landscape analysis approach reveals novel tissue architectures in ulcerative colitis](#). Holman DR, Rubin SJS, Ferenc M, Holman EA, Koron AN, Daniel R, **Boland BS**, Nolan GP, Chang JT, Rogalla S. Sci Rep. 2024 Aug 15;14(1):18934. doi: 10.1038/s41598-024-68397-5.

Boland, Richard (9)

- [Molecular Signatures for Microbe-Associated Colorectal Cancers](#). Sayed IM, Vo DT, Alcantara J, Inouye KM, Pranadinata RF, Luo L, **Boland CR**, Goyal NP, Kuo DJ, Huang SC, Sahoo D, Ghosh P, Das S. bioRxiv [Preprint]. 2024 May 27;2024.05.26.595902. doi: 10.1101/2024.05.26.595902.
- [Taming Lynch Syndrome: The Remarkable Power of Prevention for One Family](#). Yurgelun MB, Rhees J, Papadopoulos N, Vogelstein B, **Boland CR**. Gastroenterology. 2024 Jul 20:S0016-5085(24)05224-7. doi: 10.1053/j.gastro.2024.06.037. Online ahead of print.
- [Genetic Testing in Colorectal Cancer: Towards a Better Understanding and Utilization by Clinicians](#). Vargas A, Saadeh M, **Boland CR**, Goudar RK, Johnson DA. J Clin Gastroenterol. 2024 Jul 24. doi: 10.1097/MCG.0000000000002047. Online ahead of print.
- [MSH6-proficient crypt foci in MSH6 constitutional mismatch repair deficiency: reversion of a frameshifted coding microsatellite to its wild-type sequence](#). Shia J, Sanchez-Vega F, Cho S, Chen JF, Chen CT, Bhanot U, Urganci N, Firat C, Ntiamoah P, Isidro RA, Srivastava A, Weiser MR, Mandelker D, Vakiani E, **Boland CR**, Garcia-Aguilar J, Stadler ZK. Fam Cancer. 2024 Nov;23(4):569-577. doi: 10.1007/s10689-024-00423-x. Epub 2024 Oct 10. PMID: 39387980; PMCID: PMC11723700.
- [Interdisciplinary systems may restore the healthcare professional-patient relationship in electronic health systems](#). Cauley MR, **Boland RJ** Jr, Rosenbloom ST. J Am Med Inform Assoc. 2025 Jan 17;ocaf001. doi: 10.1093/jamia/ocaf001. Epub ahead of print. PMID: 39823373.

Brenner, David (23)

- [Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2](#). Ganguly S, Rosenthal SB, Ishizuka K, Troutman TD, Rohm TV, Khader N, Aleman-Muench G, Sano Y, Archilei S, Soroosh P, Olefsky JM, Feldstein AE, Kisseleva T, Loomba R, Glass CK, **Brenner DA**, Dhar D. Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2405746121. doi: 10.1073/pnas.2405746121. Epub 2024 Aug 22. PMID: 39172787
- [Role of Hepatic Stellate and Liver Sinusoidal Endothelial Cells in a Human Primary Cell Three-Dimensional Model of Nonalcoholic Steatohepatitis](#). Tan PK, Ostertag T, Rosenthal SB, Chilín-Fuentes D, Aidnik H, Linker S, Murphy K, Miner JN, **Brenner DA**. Am J Pathol. 2024 Mar;194(3):353-368. doi: 10.1016/j.ajpath.2023.12.005. Epub 2023 Dec 28. PMID: 38158078

- [Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease](#). Kim HY, Rosenthal SB, Liu X, Miciano C, Hou X, Miller M, Buchanan J, Poirion OB, Chilin-Fuentes D, Han C, Housseini M, Carvalho-Gontijo Weber R, Sakane S, Lee W, Zhao H, Diggle K, Preissl S, Glass CK, Ren B, Wang A, **Brenner DA**, Kisseleva T. J Hepatol. 2024 Nov 8:S0168-8278(24)02667-9. doi: 10.1016/j.jhep.2024.10.044. Epub ahead of print. PMID: 39522884.
- [Induction of MASH in three-dimensional bioprinted human liver tissue](#). Joshi V, Carter D, Chen AE, Murphy K, Higgins JW, Gurel M, Chilin Fuentes D, Rosenthal SB, Fisch KM, Kisseleva T, **Brenner DA**. PLoS One. 2024 Dec 30;19(12):e0312615. doi: 10.1371/journal.pone.0312615. PMID: 39775546; PMCID: PMC11684678.
- [LARP6 regulates the mRNA translation of fibrogenic genes in liver fibrosis](#). Kim HY, Mizrahi O, Lee W, Rosenthal SB, Han C, Yee BA, Blue SM, Diaz J, Jonnalagadda J, Hokutan K, Jang H, Ma CT, Bobkov A, Sergienko E, Jackson MR, Stefanovic B, Kisseleva T, Yeo GW, **Brenner DA** bioRxiv [Preprint]. 2025 Jan 18:2025.01.16.633226. doi: 10.1101/2025.01.16.633226. PMID: 39868246; PMCID: PMC11761402.

Carethers, John (15)

- [High-throughput sequencing and in-silico analysis confirm pathogenicity of novel MSH3 variants in African American colorectal cancer](#). Rashid M, Rashid R, Gadewal N, **Carethers JM**, Koi M, Brim H, Ashktorab H. Neoplasia. 2024 Mar;49:100970. doi: 10.1016/j.neo.2024.100970. Epub 2024 Jan 27. PMID: 38281411
- [Quality measures in the delivery of equitable endoscopic care to traditionally underserved patients in the United States](#). ASGE Quality Assurance in Endoscopy Committee; Williams KN, May FP, Cummings LC, Srivastava N, Shahidi N, Kohansal A, Panganamamula K, Garg R, Singh A, Green B, Nguyen JC, Essex EA, **Carethers JM**, Elmunzer BJ. Gastrointest Endosc. 2024 Oct 18:S0016-5107(24)03325-X. doi: 10.1016/j.gie.2024.06.030. Epub ahead of print. PMID: 39425707.
- [Improving Noninvasive Colorectal Cancer Screening](#). **Carethers JM**. N Engl J Med. 2024 Mar 14;390(11):1045-1046. doi: 10.1056/NEJMe2400366. PMID: 38477992
- [Contributions to Colorectal Cancer Disparities](#). **Carethers JM**. JAMA Oncol. 2024 Sep 12. doi: 10.1001/jamaoncol.2024.3516. Online ahead of print. PMID: 39264600
- [Compound heterozygous MSH3 germline variants and associated tumor somatic DNA mismatch repair dysfunction](#). Koi M, Leach BH, McGee S, Tseng-Rogenski SS, Burke CA, **Carethers JM**. NPJ Precis Oncol. 2024 Jan 19;8(1):12. doi: 10.1038/s41698-024-00511-2. PMID: 38243056

Chang, John (18)

- [IBD Matchmaking - Rational Combination Therapy](#). Battat R, **Chang JT**, Loftus EV Jr, Sands BE. Clin Gastroenterol Hepatol. 2024 Jul 25:S1542-3565(24)00633-5. doi: 10.1016/j.cgh.2024.05.051. Online ahead of print. PMID: 39025253
- [Automated spatial omics landscape analysis approach reveals novel tissue architectures in ulcerative colitis](#). Holman DR, Ruben SJS, Ferenc M, Holman EA, Koron AN, Daniel R, Boland BS, Nolan GP, **Chang JT**, Rogalla S. Sci Rep. 2024 Aug 15;14(1):18934. doi: 10.1038/s41598-024-68397-5. PMID: 39147769
- [Tissue-resident memory CD8 T cell diversity is spatiotemporally imprinted](#). Reina-Campos M, Monell A, Ferry A, Luna V, Cheung KP, Galletti G, Scharping NE, Takehara KK, Quon S, Challita PP, Boland B, Lin YH, Wong WH, Indralingam CS, Neadeau H, Alarcón S, Yeo GW, **Chang JT**, Heeg M, Goldrath AW. Nature. 2025 Jan 22. doi: 10.1038/s41586-024-08466-x. Epub ahead of print. PMID: 39843748.
- [Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists](#). Lee HH, Solitano V, Singh S, Ananthakrishnan AN, Jairath V, Syal G, Boland BS, Ghosh P, **Chang JT**, Singh S. Clin Gastroenterol Hepatol. 2024 Dec 26:S1542-3565(24)01132-7. doi: 10.1016/j.cgh.2024.12.007. Epub ahead of print. PMID: 39732355.

Chang, Michael (2)

- [Diagnostic methods to measure spastic segment and guide tailored myotomy length in type 3 achalasia](#). Low EE, Hasan A, Fehmi SA, **Chang MA**, Kwong W, Krinsky ML, Anand G, Greytak M, Kaizer A, Yadlapati R. Neurogastroenterol Motil. 2023 Jun 8; e14625. doi: 10.1111/nmo.14625.
- [Esophageal anatomy and physiology vary across spastic and non-spastic phenotypes of disorders of esophagogastric junction outflow](#). Vahedi F, Low EE, Kaizer AM, Fehmi SA, Hasan A, **Chang MA**, Kwong W, Krinsky ML, Anand G, Greytak M, Yadlapati R. Neurogastroenterol Motil. 2023 Nov 27:e14709. doi: 10.1111/nmo.14709.

Chen, Kay (2)

- [Appendiceal adenocarcinoma is associated with better prognosis than cecal adenocarcinoma: A population-based comparative survival study](#). Chen G, **Chen K**, Sahyoun L, Zaman S, Protiva P. BMJ Open Gastroenterol. 2023 Feb; 10(1): e001045. doi: 10.1136/bjgast-2022-001045.
- [Clinical and socioeconomic determinants of survival in biliary tract adenocarcinomas](#). Sahyoun L, **Chen K**, Tsay C, Chen G, Protiva P. World J Gastrointest Oncol. 2024 Apr 15;16(4):1374-1383. doi: 10.4251/wjgo.v16.i4.1374. PMID: 38660666

Copur-Dahi, Nedret (1)

- [Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease](#). Nouredin N, **Copur-Dahi N**, Loomba R. Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1(Suppl 1):S41-S51. doi: 10.1111/apt.17752. PMID: 38813822; PMCID: PMC11141723.

Dave, Shravan (5)

- [Editorial: NAFLD, NAFLD, or MASLD: what's in a name?](#) Zafer M, **Dave S**. Aliment Pharmacol Ther. 2024 Sep;60(5):648-649. doi: 10.1111/apt.18039. PMID: 39136696
- [The Study of Correlation between Symptoms of Gastritis and Endoscopic Biopsy](#). **Dave SR**, Bagada JB, Desai JH, Jha S. J West Afr Coll Surg. 2024 Oct-Dec;14(4):364-369. doi: 10.4103/jwas.jwas_96_23. Epub 2024 Jul 18. PMID: 39309390
- [Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis](#). Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, Barakat F, Hassanein TI, **Dave S**, Ajmera V, Bhooi S, Mazzaferro V, Chascsa DMH, Liu MC, Aby ES, Lake JR, Sogbe M, Sangro B, Abdelrahim M, Esmail A, Schmiderer A, Chouik Y, Rudolph M, Sohal D, Giudicelli H, Allaire M, Akce M, Guadagno J, Tow CY, Massoumi H, De Simone P, Kang E, Gartrell RD, Martinez M, Paz-Fumagalli R, Toskich BB, Tran NH, Solino GA, Poltronieri Pacheco DM, Kalman RS, Agopian VG, Mehta N, Parikh ND, Singal AG, Yang JD. J Hepatol. 2025 Jan;82(1):107-119. doi: 10.1016/j.jhep.2024.06.042. Epub 2024 Jul 10. PMID: 38996924; PMCID: PMC11655254.
- [Editorial: Checkpoint Inhibitor-Induced Liver Injury-Time to Abandon CTCAE?](#) Torosian K, **Dave S**. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1621-1622. doi: 10.1111/apt.18308. Epub 2024 Oct 14. PMID: 39400906.
- [Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study](#). Xu E, Tabrizian P, Gutierrez J, Hoteit M, Ghaziani T, Zhou K, Parikh N, Ajmera V, Aby E, Shui A, Marino R, Martin A, Wong C, Kao K, **Dave S**, Florman S, Yao F, Mehta N. Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001231. Epub ahead of print. PMID: 39808828.

Docherty, Michael (1)

- [The CIC-2 chloride channel activator, lubiprostone, improves intestinal barrier function in biopsies from Crohn's disease but not ulcerative colitis patients](#). Park YS, Kang SB, Marchelletta RR, Penrose HM, Ruiter-Visser R, Jung B, **Docherty MJ**, Boland BS, Sandborn WJ, McCole DF. Pharmaceutics 2023 Mar 2; 15(3): 811. Doi: 10.3390/pharmaceutics15030811.

Eckmann, Lars (13)

- [Mucosal vaccination in a murine gnotobiotic model of Giardia lamblia infection](#). Ihara S, Nguyen BV, Miyamoto Y, **Eckmann L**. Infect Immun. 2024 Jun 11;92(6):e0006524. doi: 10.1128/iai.00065-24. Epub 2024 May 9. PMID: 38722167
- [Antigiardial and antiamebic activities of fexinidazole and its metabolites: New drug lead for giardiasis and amebiasis](#). Escrig JI, Miyamoto Y, Aznar AD, **Eckmann L**, Debnath A. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0073123. doi: 10.1128/aac.00731-23. Epub 2023 Dec 8.
- [Structural elucidation of recombinant Trichomonas vaginalis 20S proteasome bound to covalent inhibitors](#). Silhan J, Fajtova P, Bartosova J, Hurysz BM, Almaliti J, Miyamoto Y, **Eckmann L**, Gerwick WH, O'Donoghue AJ, Boura E. Nat Commun. 2024 Oct 4;15(1):8621. doi: 10.1038/s41467-024-53022-w. PMID: 39366995; PMCID: PMC11452676.
- [Distinct substrate specificities of the three catalytic subunits of the Trichomonas vaginalis proteasome](#). Fajtova P, Hurysz BM, Miyamoto Y, Serafim MSM, Jiang Z, Vazquez JM, Trujillo DF, Liu LJ, Somani U, Almaliti J, Myers SA, Caffrey CR, Gerwick WH, McMinn DL, Kirk CJ, Boura E, **Eckmann L**, O'Donoghue AJ. Protein Sci. 2024 Dec;33(12):e5225. doi: 10.1002/pro.5225. PMID: 39589076; PMCID: PMC11590128.
- [Vaginal Trichomonas foetus infection in mice as an in vivo model for drug development against Trichomonas vaginalis](#). Nieskens NM, Miyamoto Y, Hurysz BM, O'Donoghue AJ, **Eckmann L**. PLoS One. 2024 Oct 1;19(10):e0308672. doi: 10.1371/journal.pone.0308672. PMID: 39352907; PMCID: PMC11444383.

Fehmi, Syed (3)

- [Diagnostic methods to measure spastic segment and guide tailored myotomy length in type 3 achalasia](#). Low EE, Hasan A, **Fehmi SA**, Chang MA, Kwong W, Krinsky ML, Anand G, Greytak M, Kaizer A, Yadlapati R. Neurogastroenterol Motil. 2023 Jun 8; e14625. doi:10.1111/nmo.14625.
- [Pancreatic cyst features predict for future development of pancreatic cancer: Results of a nested case-control study](#). Youssef FF, Liu L, Lin W, Bustamante R, Earles A, Savides T, **Fehmi S**, Kwong W, Gupta S, Anand G. Gastrointest Endosc. 2023 Oct 17:S0016-5107(23)02978-4. doi: 10.1016/j.gie.2023.10.038. Online ahead of print.
- [Tailored myotomy for the treatment of type 3 achalasia: Is there a role for the functional lumen imaging probe?](#) Low EE, Hasan A, **Fehmi SA**, Chang MA, Kwong W, Krinsky ML, Anand G, Greytak M, Kaizer A, Yadlapati R. Neurogastroenterol Motil. 2023 Dec;35(12):e14625. doi: 10.1111/nmo.14625. Epub 2023 Jun 8.

Gupta, Samir (37)

- [A pragmatic randomized trial of mailed fecal immunochemical testing to increase colorectal cancer screening among low-income and minoritized populations.](#) Martínez ME, Roesch S, Largaespada V, Castañeda SF, Nodora JN, Rabin BA, Covin J, Ortwine K, Preciado-Hidalgo Y, Howard N, Schultz J, Stamm N, Ramirez D, Halpern MT, **Gupta S**. Cancer. 2024 Sep 15;130(18):3170-3179. doi: 10.1002/cncr.35369. Epub 2024 May 25. PMID: 38795024; PMCID: PMC11347112.
- [Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.](#) Hodan R, **Gupta S**, Weiss JM, Axell L, Burke CA, Chen LM, Chung DC, Clayback KM, Felder S, Foda Z, Giardiello FM, Grady W, Gustafson S, Hagemann A, Hall MJ, Hampel H, Idos G, Joseph N, Kassem N, Katona B, Kelly K, Kieber-Emmons A, Kupfer S, Lang K, Llor X, Markowitz AJ, Prats MM, Niell-Swiller M, Outlaw D, Pirzadeh-Miller S, Samadder NJ, Shibata D, Stanich PP, Swanson BJ, Szymaniak BM, Welborn J, Wiesner GL, Yurgelun MB, Dwyer M, Darlow S, Diwan Z. J Natl Compr Canc Netw. 2024 Dec;22(10):695-711. doi: 10.6004/jnccn.2024.0061. PMID: 39689429.
- [Racial and Ethnic Variation in Survival in Early-Onset Colorectal Cancer.](#) Demb J, Gomez SL, Canchola AJ, Qian A, Murphy JD, Winn RA, Banegas MP, **Gupta S**, Martinez ME. JAMA Netw Open. 2024 Nov 4;7(11):e2446820. doi: 10.1001/jamanetworkopen.2024.46820. PMID: 39576642; PMCID: PMC11584933.
- [Colorectal Neoplasia in Asian Americans Undergoing First Time Asymptomatic Average-risk Screening Colonoscopies.](#) Chen B, Hsia K, Loscalzo K, Fai C, **Gupta S**, Jangi S. J Clin Gastroenterol. 2024 Nov-Dec 01;58(10):1011-1015. doi: 10.1097/MCG.0000000000001969. Epub 2024 Jan 29. PMID: 38277503.
- [Improving colonoscopy quality in the national VA healthcare system.](#) Gawron AJ, Bailey T, Codden R, Dominitz J, **Gupta S**, Helfrich C, Kahi C, Krop L, Malvar C, McKee G, Millar M, Mog A, Nguyen-Vu T, Patterson O, Presson AP, Saini S, Whooley M, Yao Y, Zickmund S, Kaltenbach T. Contemp Clin Trials. 2025 Feb;149:107784. doi: 10.1016/j.cct.2024.107784. Epub 2024 Dec 25. PMID: 39730079.

Hsu, Cynthia (10)

- [From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research.](#) **Hsu CL**, Loomba R. Nat Metab. 2024 Apr;6(4):600-602. doi: 10.1038/s42255-024-00985-1. PMID: 38383845; PMCID: PMC11262457.
- [Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis.](#) Yamazaki T, Kouno T, **Hsu CL**, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna EC, Abalde JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Schnabl B; AlcHepNet Investigators. Hepatology. 2024 Aug 1;80(2):403-417. doi: 10.1097/HEP.0000000000000777. Epub 2024 Feb 20. PMID: 38377466; PMCID: PMC11268475.
- [Fecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.](#) Kreimeyer H, Gonzalez CG, Fondevila MF, **Hsu CL**, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna EC, Abalde JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez DJ, Schnabl B. Gut. 2024 Jul 20:gutjnl-2024-332730. doi: 10.1136/gutjnl-2024-332730. Epub ahead of print. PMID: 39033024.
- [Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.](#) **Hsu CL**, Wang L, Maestri E, Jacob AR, Do WL, Mayo S, Bosques-Padilla F, Verna EC, Abalde JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Investigators A, Wang XW, Schnabl B. Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001046. Epub ahead of print. PMID: 39325984.
- [Alcohol Use Disorder and the Gut-Brain Axis: A Narrative Review of the Role of Gut Microbiota and Implications for Treatment.](#) Shukla S, **Hsu CL**. Microorganisms. 2025 Jan 2;13(1):67. doi: 10.3390/microorganisms13010067. PMID: 39858835; PMCID: PMC11767426.

Kono, Yuko (14)

- [Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.](#) Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, **Kono Y**, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Hepatology. 2024 Jul 1;80(1):87-101. doi: 10.1097/HEP.0000000000000800. Epub 2024 Feb 20. PMID: 38381705; PMCID: PMC11191046.
- [Liver Imaging Reporting and Data System Contrast-Enhanced US Nonradiation Treatment Response Assessment Version 2024.](#) Lyshchik A, Fetzter DT, **Kono Y**, Wilson SR, Dietrich CF, Clevert DA, Meloni MF, Jang HJ, Kim TK, Lee JM, Minami Y, Kudo M, Piscaglia F. Radiology. 2024 May;311(2):e232369. doi: 10.1148/radiol.232369. PMID: 38805727; PMCID: PMC11140523.

- [Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT/MRI in patients at risk for HCC](#). Kono Y, Piscaglia F, Wilson SR, Medellin A, Rodgers SK, Planz V, Kamaya A, Fetzer DT, Berzigotti A, Sidhu PS, Wessner CE, Bradigan K, Kuon Yeng Escalante CM, Siu Xiao T, Eisenbrey JR, Forsberg F, Lyshchik A; CEUS LI-RADS Trial Group. *Abdom Radiol (NY)*. 2024 Aug;49(8):2639-2649. doi: 10.1007/s00261-024-04305-9. Epub 2024 Jun 11. PMID: 38860996; PMCID: PMC11300564.
- [Spatial omics-based machine learning algorithms for the early detection of hepatocellular carcinoma](#). Wang M, Grauzam S, Bayram MF, Dressman J, DelaCourt A, Blaschke C, Liang H, Scott D, Huffman G, Black A, Ochoa-Rios S, Lewin D, Angel PM, Drake RR, Ball L, Bethard J, Castellino S, Kono Y, Kubota N, Hoshida Y, Quirk L, Yopp A, Gopal P, Singal A, Mehta AS. *Commun Med (Lond)*. 2024 Dec 3;4(1):258. doi: 10.1038/s43856-024-00677-7. PMID: 39627514; PMCID: PMC11614901.
- [Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI](#). Lyshchik A, Kuon Yeng Escalante C, Siu Xiao T, Piscaglia F, Kono Y, Medellin-Kowalewski A, Rodgers SK, Planz V, Kamaya A, Fetzer DT, Berzigotti A, Radu IP, Sidhu PS, Wessner CE, Bradigan K, Eisenbrey JR, Forsberg F, Wilson SR; CEUS LI-RADS Trial Group; CEUS LI-RADS Trial Group Members. *Radiology*. 2025 Jan;314(1):e240916. doi: 10.1148/radiol.240916. PMID: 39835975; PMCID: PMC11783161.

Krinsky, Mary Lee (1)

- [The hospital frailty risk score as a predictor of readmission after ERCP](#). Le KHN, Qian AS, Nguyen M, Qiao E, Nguyen P, Singh S, Krinsky ML. *Surg Endosc*. 2024 Jan;38(1):260-269. doi: 10.1007/s00464-023-10531-x. Epub 2023 Nov 21. PMID: 37989888

Kunkel, David (2)

- [Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 \(NHE3\)](#). Lacy BE, Rosenbaum D, Edelstein S, Kozuka K, Williams LA, Kunkel DC. *Clin Exp Gastroenterol*. 2024 Jun 6;17:173-183. doi: 10.2147/CEG.S455101. PMID: 38860153; PMCID: PMC11164200.
- [A Multidisciplinary Assessment of ChatGPT's Knowledge of Amyloidosis: Observational Study](#). King RC, Samaan JS, Yeo YH, Peng Y, Kunkel DC, Habib AA, Ghashghaei R. *JMIR Cardio*. 2024 Apr 19;8:e53421. doi: 10.2196/53421. PMID: 38640472; PMCID: PMC11069089.

Kwong, Wilson (3)

- [Pancreatic cyst features predict for future development of pancreatic cancer: Results of a nested case-control study](#). Youssef FF, Liu L, Lin W, Bustamante R, Earles A, Savides T, Fehmi S, Kwong W, Gupta S, Anand G. *Gastrointest Endosc*. 2023 Oct 17:S0016-5107(23)02978-4. doi: 10.1016/j.gie.2023.10.038. Online ahead of print.
- [Esophageal anatomy and physiology vary across spastic and non-spastic phenotypes of disorders of esophagogastric junction outflow](#). Vahedi F, Low EE, Kaizer AM, Fehmi SA, Hasan A, Chang MA, Kwong W, Krinsky ML, Anand G, Greytak M, Yadlapati R. *Neurogastroenterol Motil*. 2023 Nov 27:e14709. doi: 10.1111/nmo.14709.

Llorente, Cristina (12)

- [Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease](#). Raya Tonetti F, Eguileor A, Mrdjen M, Pathak V, Travers J, Nagy LE, Llorente C. *Hepatology*. 2024 May 1. doi: 10.1097/HEP.0000000000000924. Epub ahead of print. PMID: 38691396.
- [IL-22 resolves MASLD via enterocyte STAT3 restoration of diet-perturbed intestinal homeostasis](#). Zhang P, Liu J, Lee A, Tsaur I, Ohira M, Duong V, Vo N, Watari K, Su H, Kim JY, Gu L, Zhu M, Shalapour S, Hosseini M, Bandyopadhyay G, Zeng S, Llorente C, Zhao HN, Lamichhane S, Mohan S, Dorrestein PC, Olefsky JM, Schnabl B, Soroosh P, Karin M. *Cell Metab*. 2024 Oct 1;36(10):2341-2354.e6. doi: 10.1016/j.cmet.2024.08.012. Epub 2024 Sep 23. PMID: 39317186.
- [The Imperative for Innovative Enteric Nervous System-Intestinal Organoid Co-Culture Models: Transforming GI Disease Modeling and Treatment](#). *Cells*. Llorente C. 2024 May 10;13(10):820. doi: 10.3390/cells13100820. PMID: 38786042; PMCID: PMC11119846.
- [Commentary on the gut microbiome in alcohol use disorder and alcohol-associated liver disease](#). Llorente C. *Alcohol Clin Exp Res (Hoboken)*. 2024 Aug;48(8):1466-1468. doi: 10.1111/acer.15382. Epub 2024 Jun 2. PMID: 38825713; PMCID: PMC11305903.
- [Goblet cells: guardians of gut immunity and their role in gastrointestinal diseases](#). Tonetti FR, Eguileor A, Llorente C. *eGastroenterology*. 2024 Oct;2(3):e100098. doi: 10.1136/egastro-2024-100098. PMID: 39524932; PMCID: PMC11542612.

Loomba, Rohit (12)

- [MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.](#) **Loomba R**, Amangurbanova M, Bettencourt R, Madamba E, Siddiqi H, Richards L, Behling C, Sirlin CB, Gottwald MD, Feng S, Margalit M, Huang DQ. Gut. 2024 Jul 11;73(8):1343-1349. doi: 10.1136/gutjnl-2023-331401. PMID: 38418210. [Cut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease.](#) Raya Tonetti F, Eguileor A, Mrdjen M, Pathak V, Travers J, Nagy LE, Llorente C. Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000924. Epub ahead of print. PMID: 38691396.
- [Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.](#) **Loomba R**, Clark G, Teckman J, Ajmera V, Behling C, Brantly M, Brenner D, D'Armiento J, Fried MW, Iyer JS, Mandorfer M, Rockey DC, Tincopa M, Vuppalanchi R, Younossi Z, Krag A, Turner AM, Strnad P. Aliment Pharmacol Ther. 2024 May;59(10):1183-1195. doi: 10.1111/apt.17967. Epub 2024 Mar 22. PMID: 38516814.
- [Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD.](#) **Loomba R**, Ramji A, Hassanein T, Yoshida EM, Pang E, Schneider C, Curry MP, Afdhal NH. Hepatol Commun. 2024 Mar 22;8(4):e0402. doi: 10.1097/HC9.0000000000000402. PMID: 38517204; PMCID: PMC10962894
- [Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.](#) **Loomba R**, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikoobie A, Bunck MC, Haupt A, Sanyal AJ; SYNERGY-NASH Investigators. N Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8. PMID: 38856224.
- [Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial.](#) **Loomba R**, Bedossa P, Grimmer K, Kemble G, Bruno Martins E, McCulloch W, O'Farrell M, Tsai WW, Cobiella J, Lawitz E, Rudraraju M, Harrison SA. Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1090-1100. doi: 10.1016/S2468-1253(24)00246-2. Epub 2024 Oct 11. PMID: 39396529.

Low, Eric (16)

- [Risk of Esophageal Cancer in Achalasia: A Matched Cohort Study Using the Nationwide Veterans Affairs Achalasia Cohort.](#) **Low EE**, Demb J, Shah SC, Liu L, Bustamante R, Yadlapati R, Gupta S. Am J Gastroenterol. 2024 Apr 1;119(4):635-645. doi: 10.14309/ajg.00000000000002591. Epub 2023 Nov 17. PMID: 37975607; PMCID: PMC10994742.
- [Normative high resolution esophageal manometry values in asymptomatic patients with obesity.](#) Le KHN, **Low EE**, Sharma P, Greytak M, Yadlapati R. Neurogastroenterol Motil. 2024 Sep 17:e14914. doi: 10.1111/nmo.14914. Epub ahead of print. PMID: 39289911.
- [Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases.](#) **Low EE**, Dellon ES. Review article: Aliment Pharmacol Ther. 2024 Feb;59(3):322-340. doi: 10.1111/apt.17845. Epub 2023 Dec 22.
- [Eosinophils Are Just the Tip of the Iceberg for Eosinophilic Esophagitis.](#) Gastroenterology. **Low EE**, Yadlapati R. 2024 Oct 10:S0016-5085(24)05568-9. doi: 10.1053/j.gastro.2024.10.006. Epub ahead of print. PMID: 39393542.
- [The First Approved Therapy in Infants and Young Children With EoE - Now the Big Question: Where Will Dupilumab Fit Into Real-World Practice?](#) **Low EE**, Yadlapati R. Gastroenterology. 2024 Oct 10:S0016-5085(24)05569-0. doi: 10.1053/j.gastro.2024.10.007. Epub ahead of print. PMID: 39393541.

Mittal, Ravinder (6)

- [Esophageal Symptoms and Lumbosacral Back Pain.](#) **Mittal RK**, Le C, Ledgerwood M, Jung DK, Gandu V, Zifan A. Gastro Hep Adv. 2024;3(2):292-299. doi: 10.1016/j.gastha.2023.11.003. Epub 2023 Nov 21. PMID: 38645466; PMCID: PMC11027073.
- [Enhancing the diagnostic yield of esophageal manometry using distension-contraction plots of peristalsis and artificial intelligence.](#) Zifan A, Lee JM, **Mittal RK**. Am J Physiol Gastrointest Liver Physiol. 2024 Sep 1;327(3):G405-G413. doi: 10.1152/ajpgi.00139.2024. Epub 2024 Jul 2. PMID: 38953836; PMCID: PMC11427102.
- [Fecal incontinence patients categorized based on anal pressure and electromyography: Anal sphincter damage and clinical symptoms.](#) Swartz JL, Zifan A, Tuttle LJ, Sheean G, Tam RM, **Mittal RK**. Neurogastroenterol Motil. 2024 Jul;36(7):e14810. doi: 10.1111/nmo.14810. Epub 2024 Apr 30. PMID: 38689439.
- [Selective dysfunction of the crural diaphragm in patients with chronic restrictive and obstructive lung disease.](#) Joshua J, Pathak C, Zifan A, Chen R, Malhotra A, **Mittal RK**. Neurogastroenterol Motil. 2024 Jan;36(1):e14699. doi: 10.1111/nmo.14699. Epub 2023 Oct 26.

Noureddin, Nabil (4)

- [A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia.](#) Amangurbanova M, Huang DQ, **Noureddin N**, Tesfai K, Bettencourt R, Siddiqi H, Lopez SJ, Cervantes V, Madamba E, Loomba R. Aliment Pharmacol Ther. 2025 Feb;61(3):456-464. doi: 10.1111/apt.18377. Epub 2024 Nov 5. PMID: 39499168.
- [Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.](#) **Noureddin N**, Copur-Dahi N, Loomba R. Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1(Suppl 1):S41-S51. doi: 10.1111/apt.17752. PMID: 38813822; PMCID: PMC11141723.
- [Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.](#) **Noureddin N**, Huang DQ, Bettencourt R, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Gidener T, Allen AM, Ajmera V, Loomba R. Aliment Pharmacol Ther. 2024 Jun;59(12):1521-1526. doi: 10.1111/apt.17981. Epub 2024 Apr 3. PMID: 38571305.
- [Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.](#) Lee SW, Huang DQ, Bettencourt R, Ajmera V, Tincopa M, **Noureddin N**, Amangurbanova M, Siddiqi H, Madamba E, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Yoneda M, Idilman R, Gumussoy M, Oz DK, Erden A, Loomba R. Aliment Pharmacol Ther. 2024 Jan;59(1):80-88. doi: 10.1111/apt.17783. Epub 2023 Nov 15. Erratum in: Aliment Pharmacol Ther. 2024 Feb;59(3):427. doi: 10.1111/apt.17854. PMID: 37968251; PMCID: PMC10807727.

Patton, Heather (11)

- [Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.](#) Chen VL, Morgan TR, Rotman Y, **Patton HM**, Cusi K, Kanwal F, Kim WR. Hepatology. 2025 Jan 1;81(1):312-320. doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18. PMID: 39422487.
- [Identifying and treating metabolic dysfunction-associated steatotic liver disease among at-risk Veterans.](#) Niezen S, Morgan TR, Scott D, Yakovchenko V, **Patton H**, Spoutz P, Yao Y, Baffy G, Fuchs M, Bajaj JS, Ekanem NR, Dominitz JA, Rogal SS. Am J Gastroenterol. 2025 Jan 7. doi: 10.14309/ajg.0000000000003312. Epub ahead of print. PMID: 39774063.
- [Screening high-risk Veterans for cirrhosis: taking a stepwise population health approach.](#) Dounel J, Lamorte C, **Patton H**, Perumalswami P, McCurdy H, Kim NJ, Beste LA, Scott D, Casey J, Spoutz P, Chia L, Yao Y, Lowy E, Gibson S, Morgan TR, Rogal SS. BMC Health Serv Res. 2025 Jan 29;25(1):168. doi: 10.1186/s12913-025-12216-8. PMID: 39875981; PMCID: PMC11776120.
- [A machine-learning model score predicts advanced fibrosis and cirrhosis in indeterminate FIB-4 patients.](#) Niezen S, Morgan TR, **Patton HM**, Bajaj JS, Tapper EB, Rogal SS. Clin Gastroenterol Hepatol. 2025 Jan 30:S1542-3565(25)00077-1. doi: 10.1016/j.cgh.2024.12.020. Epub ahead of print. PMID: 39892634.
- [Organizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration.](#) McCurdy H, Nobbie A, Scott D, **Patton H**, Morgan TR, Bajaj JS, Yakovchenko V, Merante M, Gibson S, Lamorte C, Baffy G, Ioannou GN, Taddei TH, Rozenberg-Ben-Dror K, Anwar J, Dominitz JA, Rogal SS. Dig Dis Sci. 2024 Jun;69(6):2008-2017. doi: 10.1007/s10620-024-08409-6. Epub 2024 Apr 14. PMID: 38616215.

Rivera-Nieves, Jesus (4)

- [Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management.](#) Kitsou K, Kokkotis G, **Rivera-Nieves J**, Bamias G. Drugs. 2024 Sep 26. doi: 10.1007/s40265-024-02094-5. Epub ahead of print. PMID: 39322927.
- [Vedolizumab Does Not Affect Antibody Secreting Cell Recruitment to the Lactating Mammary Gland of Mothers With Inflammatory Bowel Disease.](#) Urrete J, Mitra T, Boland BS, Bertrand K, Chambers C, **Rivera-Nieves J**. Inflamm Bowel Dis. 2025 Jan 6;31(1):290-293. doi: 10.1093/ibd/izae023. PMID: 38334263; PMCID: PMC11700889.
- [S1P Lyase Inhibition Increased Intestinal S1P, Disrupted the Intestinal Barrier and Aggravated DSS-Induced Colitis.](#) Kaur P, Karuppuachamy T, Chilukuri A, Kim M, Urrete J, Shen Z, Saxon L, Lundborg LR, Mikulski Z, Jedlicka P, **Rivera-Nieves J**. Inflamm Bowel Dis. 2025 Feb 17:izaf030. doi: 10.1093/ibd/izaf030. Epub ahead of print. PMID: 39960746.
- [A Similar Mutation in the AAUU-Rich Elements of the Mouse TNF Gene Results in a Distinct Ileocolitic Phenotype: A New Strain of TNF-Overexpressing Mice.](#) Chilukuri A, Kim M, Mitra T, Gubatan JM, Urrete J, Saxon LD, Ablack A, Mikulski Z, Dobaczewska K, Shen Z, Keir M, Yi T, Kaur P, Oliveira P, Murillo-Saich J, Chang EY, Steiner CA, Jedlicka P, Guma M, **Rivera-Nieves J**. Inflamm Bowel Dis. 2025 Jan 4:izae307. doi: 10.1093/ibd/izae307. Epub ahead of print. PMID: 39756463.

Sandborn, William (43)

- [Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease](#). Khanna R, Feagan BG, Zou G, Stitt LW, McDonald JWD, Bressler B, Panaccione R, Shackelton LM, VanViegen T, Loftus EV Jr, Daperno M, Jairath V, D'Haens G, **Sandborn WJ**. Reliability and Inflamm Bowel Dis. 2024 Apr 25;:iae089. doi: 10.1093/ibd/izae089. Epub ahead of print. PMID: 38661492.
- [Pangenome comparison of Bacteroides fragilis genomospecies unveils genetic diversity and ecological insights](#). Oles RE, Carrillo Terrazas M, Loomis LR, Hsu C-Y, Tribelhorn C, Belda-Ferre P, Ea AC, Bryant M, Young JA, Carrow HC, **Sandborn WJ**, Dulai PS, Sivagnanam M, Pride D, Knight R, Chu H. mSystems. 2024 Jul 23;9(7):e0051624. doi: 10.1128/msystems.00516-24. Epub 2024 Jun 27. PMID: 38934546; PMCID: PMC11265264.
- [Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy](#). Wong R, Charilaou P, Hemperly A, Qin L, Pan Y, Mathani P, Longman R, Boland BS, Dulai PS, Holmer AK, Lukin D, Singh S, Valasek MA, **Sandborn WJ**, Scherl E, Vande Casteele N, Battat R. Crohns Colitis 360. 2024 Nov 22;6(4):otae052. doi: 10.1093/crocol/otae052. PMID: 39679163; PMCID: PMC11645457.
- [Correction to: Genetic Risk, Dysbiosis, and Treatment Stratification Using Host Genome and Gut Microbiome in Inflammatory Bowel Disease](#). Moustafa A, Li W, Anderson EL, MWong EH, Dulai PS, **Sandborn WJ**, Biggs W, Yooseph S, Jones MB, Venter CJ, Nelson KE, Chang JT, Telenti A, Boland BS. Clin Transl Gastroenterol. 2024 Dec 1;15(12):e00796. doi: 10.14309/ctg.0000000000000796. Erratum for: Clin Transl Gastroenterol. 2018 Jan 18;9(1):e132. doi: 10.1038/ctg.2017.58. PMID: 39656168; PMCID: PMC11671059.
- [Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial](#). Sands BE, Panaccione R, D'Haens G, Schreiber S, Jairath V, DuVall A, Kierkus J, Walczak M, Naik S, Gilder K, Lindstrom B, Ogilvie K, **Sandborn WJ**, Vermeire S, Rubin DT, Peyrin-Biroulet L, Danese S. Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00386-8. doi: 10.1016/S2468-1253(24)00386-8. Epub ahead of print. PMID: 39793589.

Savides, Thomas (5)

- [Pancreatic cyst features predict future development of pancreatic cancer: results of a nested case-control study](#). Youssef FF, Liu L, Lin W, Bustamante R, Earles A, **Savides T**, Fehmi S, Kwong W, Gupta S, Anand G. Gastrointest Endosc. 2024 Feb;99(2):262.e1-262.e9. doi: 10.1016/j.gie.2023.10.038. Epub 2023 Oct 17. PMID: 37858759; PMCID: PMC10865337.
- [Endoscopic Approaches for Managing Small Intestinal Disease](#). Youssef FF, Branch LL, Kowalczyk M, **Savides TJ**. Annu Rev Med. 2025 Jan;76(1):155-165. doi: 10.1146/annurev-med-060123-120109. Epub 2025 Jan 16. PMID: 39689275.
- [Learning health system research as a catalyst for promoting physician wellness: EHR InBasket Spring cleaning and team-based compassion practice](#). Tai-Seale M, Walker A, Cheng Y, Yung N, Webb S, Lunde O, Bazzo D, Mandvi A, Doran N, Kallenberg G, Longhurst CA, Zisook S, **Savides TJ**, Millen M, Liu L. Learn Health Syst. 2024 Jul 5;9(1):e10444. doi: 10.1002/lrh2.10444. PMID: 39822924; PMCID: PMC11733442.

Schnabl, Bernd (45)

- [Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis](#). Yamazaki T, Kouno T, Hsu CL, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna EC, Abrales JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, **Schnabl B**; AlcHepNet Investigators. Hepatology. 2024 Aug 1;80(2):403-417. doi: 10.1097/HEP.0000000000000777. Epub 2024 Feb 20. PMID: 38377466; PMCID: PMC11268475.
- [Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis](#). Hsu CL, Wang L, Maestri E, Jacob AR, Mayo S, Bosques-Padilla F, Verna EC, Abrales JC, Brown Jr RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, AlcHepNet Investigators, Wang XW, **Schnabl B**. Hepatology. 2024; accepted. PMID: 39325984
- [Endogenous ethanol production in health and disease](#). Meijnikman AS, Nieuwdorp M, **Schnabl B**. Nat Rev Gastroenterol Hepatol. 2024 Aug;21(8):556-571. doi: 10.1038/s41575-024-00937-w. Epub 2024 Jun 3. PMID: 38831008.
- [Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis](#). Kreimeyer H, Gonzalez CG, Fondevila MF, Hsu CL, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna EC, Abrales JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez DJ, **Schnabl B**. Gut. 2024 Jul 20:gutjnl-2024-332730. doi: 10.1136/gutjnl-2024-332730. Epub ahead of print. PMID: 39033024.
- [Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis](#). Hsu CL, Wang L, Maestri E, Jacob AR, Do WL, Mayo S, Bosques-Padilla F, Verna EC, Abrales JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Investigators A, Wang XW, **Schnabl B**. Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001046. Epub ahead of print. PMID: 39325984.

Shah, Shailja (46)

- [ACG Clinical Guideline: Treatment of Helicobacter pylori Infection](#). Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, **Shah SC**. Am J Gastroenterol. 2024 Sep 1;119(9):1730-1753. doi: 10.14309/ajg.0000000000002968. Epub 2024 Sep 4. PMID: 39626064
- [AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review](#). **Shah SC**, Wang AY, Wallace MB, Hwang JH. Gastroenterology. 2025 Feb;168(2):405-416.e1. doi: 10.1053/j.gastro.2024.11.001. Epub 2024 Dec 23. PMID: 39718517.
- [Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort](#). **Shah SC**, Camargo MC, Lamm M, Bustamante R, Roumie CL, Wilson O, Halvorson AE, Greevy R, Liu L, Gupta S, Demb JJ. Clin Oncol. 2024 Jun 1;42(16):1881-1889. doi: 10.1200/JCO.23.00703. Epub 2024 Mar 1. PMID: 38427927
- [AGA Clinical Practice Update on High-Quality Upper Endoscopy: Expert Review](#). Nagula S, Parasa S, Laine L, **Shah SC**. Clin Gastroenterol Hepatol. 2024 May;22(5):933-943. doi: 10.1016/j.cgh.2023.10.034. Epub 2024 Feb 22. PMID: 38385942
- [ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis](#). Dellon ES, Muir AB, Katzka DA, **Shah SC**, Sauer BG, Aceves SS, Furuta GT, Gonsalves N, Hirano I. Am J Gastroenterol. 2025 Jan 1;120(1):31-59. doi: 10.14309/ajg.0000000000003194. Epub 2025 Jan 2. PMID: 39745304

Singh, Siddharth (93)

- [Common Instances of Low-value Care in Inflammatory Bowel Diseases](#). Clin Gastroenterol Hepatol. **Singh S**, Velayos FS, Rubin DT. 2024 May;22(5):923-932. doi: 10.1016/j.cgh.2023.09.043. Epub 2023 Oct 23. PMID: 37879517.
- [Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn's Disease: Secondary Analysis of the PYRAMID Registry](#). Ahuja D, Luo J, Qi Y, Syal G, Boland BS, Chang J, Ma C, Jairath V, Xu R, **Singh S**. Clin Gastroenterol Hepatol. 2024 Jun;22(6):1286-1294.e4. doi: 10.1016/j.cgh.2024.01.003. Epub 2024 Jan 11. PMID: 38216022; PMCID: PMC11260264.
- [Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis](#). Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, Loftus EV Jr, **Singh S**. Gastroenterology. 2024 Dec;167(7):1460-1482. doi: 10.1053/j.gastro.2024.07.046. Epub 2024 Oct 18. PMID: 39425738.
- [AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis](#). **Singh S**, Loftus EV Jr, Limketkai BN, Haydek JP, Agrawal M, Scott FI, Ananthakrishnan AN; AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org. Gastroenterology. 2024 Dec;167(7):1307-1343. doi: 10.1053/j.gastro.2024.10.001. PMID: 39572132.
- [No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis](#). Ahuja D, Zou G, Solitano V, Syal G, Lee HH, Ma C, Jairath V, **Singh S**. Clin Gastroenterol Hepatol. 2024 Oct 11:S1542-3565(24)00877-2. doi: 10.1016/j.cgh.2024.08.040. Epub ahead of print. PMID: 39395572.

Tincopa, Monica (20)

- [New and emerging treatments for metabolic dysfunction-associated steatohepatitis](#). **Tincopa MA**, Anstee QM, Loomba R. Cell Metab. 2024 May 7;36(5):912-926. doi: 10.1016/j.cmet.2024.03.011. Epub 2024 Apr 11. Erratum in: Cell Metab. 2024 Jun 4;36(6):1430. doi: 10.1016/j.cmet.2024.04.016. PMID: 38608696.
- [Disparities for Hispanic Adults With Metabolic Dysfunction-associated Steatotic Liver Disease in the United States: A Systematic Review and Meta-analysis](#). Tesfai K, Pace J, El-Newihi N, Martinez ME, **Tincopa M**, Loomba R. Clin Gastroenterol Hepatol. 2024 Jul 16:S1542-3565(24)00637-2. doi: 10.1016/j.cgh.2024.06.038. Epub ahead of print. PMID: 39025254.
- [Opioid use and risks in candidates and recipients of liver transplant](#). Rubin JB, Aby ES, Barman P, **Tincopa M**. Liver Transpl. 2024 Apr 29. doi: 10.1097/LVT.0000000000000388. Epub ahead of print. PMID: 38669598.
- [Disparities in screening and risk stratification for hispanic adults with metabolic dysfunction-associated steatotic liver disease](#). **Tincopa MA**, Díaz LA, Huang DQ, Arab JP, Arrese M, Gadano A, Oliveira CP, Bettencourt R, Madamba E, Kim S, Siddqi H, Barreyro FJ, Marciano S, Martínez Morales J, Villela-Nogueira C, Leite N, Couto CA, Theodoro R, Joyner de Sousa Dias Monteiro M, Pessoa MG, Alvares-da-Silva MR, Higuera de la Tijera F, Sabate CD, Mendizabal M, Richards L, Sirlin CB, Loomba R. Hepatology. 2024 Oct 18. doi: 10.1097/HEP.0000000000001121. Epub ahead of print. PMID: 39423341.
- [Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA](#). Yang AH, **Tincopa MA**, Tavaglione F, Ajmera VH, Richards LM, Amangurbanova M, Butcher C, Hernandez C, Madamba E, Singh S, Bettencourt R, Schnabl B, Sirlin CB, Loomba R. Gut. 2024 Aug 7:gutjnl-2024-332917. doi: 10.1136/gutjnl-2024-332917. Epub ahead of print. PMID: 39117370.

Urtecho, Guillaume (7)

- [MCSPACE: inferring microbiome spatiotemporal dynamics from high-throughput co-localization data](#). Uppal G, **Urtecho GK**, Richardson M, Comba IY, Lee J, Moody T, Wang HH, Gerber GK. *bioRxiv* [Preprint]. 2024 Dec 7;2024.12.06.627244. doi: 10.1101/2024.12.06.627244. PMID: 39677711
- [Spatiotemporal dynamics during niche remodeling by super-colonizing microbiota in the mammalian gut](#). **Urtecho G**, Moody T, Huang Y, Sheth RU, Richardson M, Descamps HC, Kaufman A, Lekan O, Zhang Z, Velez-Cortes F, Qu Y, Cohen L, Ricaurte D, Gibson TE, Gerber GK, Thaïss CA, Wang HH. *Cell Syst*. 2024 Nov 20;15(11):1002-1017.e4. doi: 10.1016/j.cels.2024.10.007. Epub 2024 Nov 13. PMID: 39541983
- [SAMPL-seq reveals micron-scale spatial hubs in the human gut microbiome](#). Richardson M, Zhao S, Sheth RU, Lin L, Qu Y, Lee J, Moody T, Ricaurte D, Huang Y, Velez-Cortes F, **Urtecho G**, Wang HH. *bioRxiv* [Preprint]. 2024 Oct 12;2024.10.08.617108. doi: 10.1101/2024.10.08.617108. Update in: *Nat Microbiol*. 2025 Feb;10(2):527-540. doi: 10.1038/s41564-024-01914-4. PMID: 39416120
- [SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1](#). Wang Q, Guo Y, Schwanz LT, Mellis IA, Sun Y, Qu Y, **Urtecho G**, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD, Liu L. *Emerg Microbes Infect*. 2024 Dec;13(1):2359004. doi: 10.1080/22221751.2024.2359004. Epub 2024 May 31. PMID: 38779718
- [Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer](#). Ho CC, Gilbert MB, **Urtecho G**, Lee H, Drew DA, Klempner SJ, Cho JS, Ryan TJ, Rustgi N, Lee H, Lee J, Caraballo A, Magicheva-Gupta MV, Rios C, Shin AE, Tseng YY, Davis JL, Chung DC, Chan AT, Wang HH, Ryeom S. *Cancer Prev Res (Phila)*. 2024 Aug 1;17(8):361-376. doi: 10.1158/1940-6207.CAPR-23-0449. PMID: 38669694

Vande-Castele, Niels (9)

- [Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn's Disease Activity](#). Solitano V, Schaeffer DF, Hogan M, **Vande-Castele N**, Pai RK, Zou G, Pai RK, Parker CE, Rémillard J, Christensen B, Danese S, Peyrin-Biroulet L, Panaccione R, Sands BE, D'Haens G, Feagan BG, Ma C, Jairath V. *Clin Gastroenterol Hepatol*. 2024 Sep;22(9):1898-1907.e25. doi: 10.1016/j.cgh.2023.11.032. Epub 2023 Dec 4. PMID: 38056798.
- [Review article: Optimisation of biologic \(monoclonal antibody\) therapeutic response in inflammatory bowel disease](#). Chaemsupaphan T, Leong RW, **Vand- Castele N**, Seow CH. *Aliment Pharmacol Ther*. 2024 Nov;60(9):1234-1243. doi: 10.1111/apt.18228. PMID: 39403056.
- [Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy](#). Wong R, Charilaou P, Hemperly A, Qin L, Pan Y, Mathani P, Longman R, Boland BS, Dulai PS, Holmer AK, Lukin D, Singh S, Valasek MA, Sandborn WJ, Scherl E, **Vande-Castele N**, Battat R. *Crohn's Colitis* 360. 2024 Nov 22;6(4):otae052. doi: 10.1093/crocol/otae052. PMID: 39679163; PMCID: PMC11645457.
- [Identification of immune cell markers associated with ulcerative colitis histological disease activity in colonic biopsies](#). Lefevre PLC, Wang Z, Teft W, Zou G, Van Viegen T, Linggi B, Jairath V, Feagan BG, Pai RK, **Vande Castele N**. *J Clin Pathol*. 2024 Feb 28;jcp-2023-209327. doi: 10.1136/jcp-2023-209327. Online ahead of print. PMID: 38418201
- [Reverse metabolomics for the discovery of chemical structures from humans](#). Gentry EC, Collins SL, Panitchpakdi M, Belda-Ferre P, Stewart AK, Carrillo Terrazas M, Lu HH, Zuffa S, Yan T, Avila-Pacheco J, Plichta DR, Aron AT, Wang M, Jarmusch AK, Hao F, Syrkin-Nikolau M, Vlamakis H, Ananthakrishnan AN, Boland BS, Hemperly A, **Vande Castele N**, Gonzalez FJ, Clish CB, Xavier RJ, Chu H, Baker ES, Patterson AD, Knight R, Siegel D, Dorrestein PC. *Nature*. 2024 Feb;626(7998):419-426. doi: 10.1038/s41586-023-06906-8. Epub 2023 Dec 5. PMID: 38052229

Vodkin, Irene (7)

- [Psychosocial predictors of return to alcohol use after liver transplant: A multicenter cohort study](#). Torosian K, Shahrivini B, Johnson WM Jr, **Vodkin I**, Tincopa M, Lim N, Kwong A, Ajmera V. *Alcohol Clin Exp Res (Hoboken)*. 2024 Sep 10. doi: 10.1111/acer.15438. Epub ahead of print. PMID: 39256266.
- [Financial burden following adult liver transplantation is common and associated with adverse recipient outcomes](#). Ufere NN, Serper M, Kaplan A, Horick N, Indriolo T, Li L, Satapathy N, Donlan J, Castano Jimenez JC, Lago-Hernandez C, Lieber S, Gonzalez C, Keegan E, Schoener K, Bethea E, Dageforde LA, Yeh H, El-Jawahri A, Park ER, **Vodkin I**, Schonfeld E, Nipp R, Desai A, Lai JC. *Liver Transpl*. 2024 Sep 1;30(9):918-931. doi: 10.1097/LVT.0000000000000348. Epub 2024 Feb 15. PMID: 38353602; PMCID: PMC11380752.

- [Combined heart liver transplantation in the patients with advanced liver disease and/or hepatocellular carcinoma: Why cannot liver pull the heart?](#) Shingina A, Bansal N, Cedars A, Chen S, Daugherty T, Emamaullee J, Ganger D, Ge J, Heller T, Hughes D, Kay J, Ortega Legaspi J, Menachem J, Montenegro M, Sack J, Reardon L, Schiano T, Simpson K, Teuteberg J, Tompkins R, **Vodkin I**, Wu F, Lui G, Zaidi AN, Kappus M, Hilscher M. *Am J Transplant*. 2024 Mar;24(3):503-505. doi: 10.1016/j.ajt.2023.10.008. Epub 2023 Oct 13. PMID: 37839708
- [Portosystemic shunt placement reveals blood signatures for the development of hepatic encephalopathy through mass spectrometry](#). Dantas Machado AC, Ramos SF, Gauglitz JM, Fassler AM, Petras D, Aksenov AA, Kim UB, Lazarowicz M, Barnard Giustini A, Aryafar H, **Vodkin I**, Warren C, Dorrestein PC, Zarrinpar A, Zarrinpar A. *Nat Commun*. 2023 Aug 31;14(1):5303. doi: 10.1038/s41467-023-40741-9. PMID: 37652904; PMCID: PMC10471626.
- [Secondary peritonitis in a patient with cirrhosis involving *Hyphopichia burtonii*, an emerging fungal pathogen](#). Feldman EB, Bellinghausen AL, **Vodkin IE**, Abeles SR, Kamdar BB. *IDCases*. 2023 Feb 28;31:e01730. doi: 10.1016/j.idcr.2023.e01730. PMID: 36911872; PMCID: PMC9996382.

Yadlapati, Rena (56)

- [Quality Indicators for Upper GI Endoscopy](#). **Yadlapati R**, Early D, Iyer PG, Morgan DR, Sengupta N, Sharma P, Shaheen NJ. *Am J Gastroenterol*. 2025 Feb 1;120(2):290-312. doi: 10.14309/ajg.0000000000003252. Epub 2025 Jan 14. PMID: 39808581.
- [Laryngeal Recalibration Therapy Improves Laryngopharyngeal Symptoms in Patients With Suspected Laryngopharyngeal Reflux Disease](#). Walsh E, Krause AJ, Greytak M, Kaizer AM, Weissbrod PA, Liu K, Taft T, **Yadlapati R**. *Am J Gastroenterol*. 2024 Nov 1;119(11):2198-2205. doi: 10.14309/ajg.0000000000002839. Epub 2024 Apr 24. PMID: 38656937; PMCID: PMC11534515.
- [Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial](#). Laine L, Spechler S, **Yadlapati R**, Schnoll-Sussman F, Smith N, Leifke E, Harris T, Hunt B, Fass R, Katz P. *Clin Gastroenterol Hepatol*. 2024 Nov;22(11):2211-2220.e10. doi: 10.1016/j.cgh.2024.05.004. Epub 2024 May 14. PMID: 38750866
- [The Role of High-Resolution Manometry Before and Following Antireflux Surgery: The Padova Consensus](#). Salvador R, Pandolfino JE, Costantini M, Gyawali CP, Keller J, Mittal S, Roman S, Savarino EV, Tatum R, Tolone S, Zerbib F, Capovilla G, Jain A, Kathpalia P, Provenzano L, **Yadlapati R**; HRM & Foregut Surgery International Working Group. *Ann Surg*. 2025 Jan 1;281(1):124-135. doi: 10.1097/SLA.0000000000006297. Epub 2024 Apr 12. PMID: 38606560
- [Validated Clinical Score to Predict Gastroesophageal Reflux in Patients With Chronic Laryngeal Symptoms: COUGH Reflux](#). Krause AJ, Kaizer AM, Carlson DA, Chan WW, Chen CL, Gyawali CP, Jenkins A, Pandolfino JE, Polamraju V, Wong MW, Greytak M, **Yadlapati R**. *Clin Gastroenterol Hepatol*. 2024 Jun;22(6):1200-1209.e1. doi: 10.1016/j.cgh.2024.01.021. Epub 2024 Feb 2. PMID: 38309491

Youssef, Fady (4)

- [Response](#) **Youssef FF**, Gupta S, Anand G.. *Gastrointest Endosc*. 2024 Apr;99(4):663-664. doi: 10.1016/j.gie.2023.12.005. PMID: 38508812.
- [Endoscopic Approaches for Managing Small Intestinal Disease](#). **Youssef FF**, Branch LL, Kowalczyk M, Savides TJ. *Annu Rev Med*. 2025 Jan;76(1):155-165. doi: 10.1146/annurev-med-060123-120109. Epub 2025 Jan 16. PMID: 39689275.
- [Pancreatic cyst features predict future development of pancreatic cancer: results of a nested case-control study](#). **Youssef FF**, Liu L, Lin W, Bustamante R, Earles A, Savides T, Fehmi S, Kwong W, Gupta S, Anand G. *Gastrointest Endosc*. 2024 Feb;99(2):262.e1-262.e9. doi: 10.1016/j.gie.2023.10.038. Epub 2023 Oct 17. PMID: 37858759

Zarrinpar, Amir (17)

- [Time of sample collection is critical for the replicability of microbiome analyses](#). Allaband C, Lingaraju A, Flores Ramos S, Kumar T, Javaheri H, Tiu MD, Dantas Machado AC, Richter RA, Elijah E, Haddad GG, Leone VA, Dorrestein PC, Knight R, **Zarrinpar A**. *Nat Metab*. 2024 Jul;6(7):1282-1293. doi: 10.1038/s42255-024-01064-1. Epub 2024 Jul 1. PMID: 38951660; PMCID: PMC11309016.
- [Live bacterial therapeutics for detection and treatment of colorectal cancer](#). Zhang J, Hasty J, **Zarrinpar A**. *Nat Rev Gastroenterol Hepatol*. 2024 May;21(5):295-296. doi: 10.1038/s41575-024-00901-8. PMID: 38355755; PMCID: PMC11062807.
- [Engineered bacterial therapeutics for detecting and treating CRC](#). Siguenza N, Brevi A, Zhang JT, Pabani A, Bhushan A, Das M, Ding Y, Hasty J, Ghosh P, **Zarrinpar A**. *Trends Cancer*. 2024 Jul;10(7):588-597. doi: 10.1016/j.trecan.2024.04.001. Epub 2024 Apr 30. PMID: 38693003; PMCID: PMC11392429.

- [Harnessing the power within: engineering the microbiome for enhanced gynecologic health](#). Brennan C, Chan K, Kumar T, Maissy E, Brubaker L, Dothard MI, Gilbert JA, Gilbert KE, Lewis AL, Thackray VG, **Zarrinpar A**, Knight R. *Reprod Fertil*. 2024 Apr 15;5(2):e230060. doi: 10.1530/RAF-23-0060. PMID: 38513356; PMCID: PMC11046331.
- [Correction for Brennan et al., "Maximizing the potential of high-throughput next-generation sequencing through precise normalization based on read count distribution"](#). Brennan C, Salido RA, Belda-Ferre P, Bryant M, Cowart C, Tiu MD, Gonzalez A, McDonald D, Tribelhorn C, **Zarrinpar A**, Knight R. *mSystems*. 2025 Jan 21;10(1):e0128824. doi: 10.1128/msystems.01288-24. Epub 2024 Dec 13. Erratum for: *mSystems*. 2023 Aug 31;8(4):e0000623. doi: 10.1128/msystems.00006-23. PMID: 39670765; PMCID: PMC11748486.

Zifan, Ali (4)

- [Enhancing the diagnostic yield of esophageal manometry using distension-contraction plots of peristalsis and artificial intelligence](#). **Zifan A**, Lee JM, Mittal RK. *Am J Physiol Gastrointest Liver Physiol*. 2024 Sep 1;327(3):G405-G413. doi: 10.1152/ajpgi.00139.2024. Epub 2024 Jul 2. PMID: 38953836; PMCID: PMC11427102.
- [Fecal incontinence patients categorized based on anal pressure and electromyography: Anal sphincter damage and clinical symptoms](#). Swartz JL, **Zifan A**, Tuttle LJ, Sheean G, Tam RM, Mittal RK. *Neurogastroenterol Motil*. 2024 Jul;36(7):e14810. doi: 10.1111/nmo.14810. Epub 2024 Apr 30. PMID: 38689439.
- [Selective dysfunction of the crural diaphragm in patients with chronic restrictive and obstructive lung disease](#). Joshua J, Pathak C, **Zifan A**, Chen R, Malhotra A, Mittal RK. *Neurogastroenterol Motil*. 2024 Jan;36(1):e14699. doi: 10.1111/nmo.14699. Epub 2023 Oct 26.
- [Adaptive Evolutionary Optimization of Deep Learning Architectures for Focused Liver Ultrasound Image Segmentation](#). **Zifan A**, Zhao K, Lee M, Peng Z, Roney LJ, Pai S, Weeks JT, Middleton MS, Kaffas AE, Schwimmer JB, Sirlin CB. *Diagnostics (Basel)*. 2025 Jan 7;15(2):117. doi: 10.3390/diagnostics15020117. PMID: 39857001





SAVE-THE-DATE

DIVISION OF GASTROENTEROLOGY & HEPATOLOGY

DDW Reception

SUNDAY, 05.04.25

RUSTIC ROOT
535 Fifth Ave
San Diego, CA 92101

This newsletter is distributed by the Division of
Gastroenterology and Hepatology.
If you have any questions/comments or wish to be
removed from this list, please contact
giadmin@health.ucsd.edu

